Mirum Pharmaceuticals, Inc.

For the period ended Sep 30, 2026. Filed Nov 3, 2026.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Sep 30, 2026 · Filed Nov 3, 2026

MIRM$94.42+1.3%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Statements of Cash Flows

	Nine Months Ended September 30,
	2026	2025
Operating activities
Net loss	$(898,148)	$(17,633)
Reconciliation of net loss to net cash (used in) provided by operating activities:
Stock-based compensation	100,085	52,398
Depreciation and amortization	20,699	18,170
Amortization of debt discount and offering costs	1,962	1,303
Unrealized foreign exchange loss (gain)	1,824	(1,913)
Non-cash lease expense	1,743	1,273
Inventory reserves and firm commitment losses	800	2,889
Fair value of common stock issued in connection with asset acquisition	415,271	—
Debt conversion inducement expense	11,737	—
Change in fair value of holdback liabilities	(5,341)	—
Other	(929)	(1,019)
Change in operating assets and liabilities:
Accounts receivable	(39,690)	(29,047)
Prepaid and other current assets	(12,024)	(11,746)
Inventory	(2,414)	(6,166)
Other assets	(10,085)	(4,026)
Accounts payable, accrued expenses and other liabilities	67,375	46,660
Holdback liabilities	71,529	—
Operating lease liabilities	(1,720)	(1,383)
Net cash (used in) provided by operating activities	(277,326)	49,760
Investing activities
Purchase of investments	(249,375)	(85,923)
Proceeds from maturities of investments	85,939	61,317
Purchase of property and equipment	(1,992)	(354)
Payments made for additions to intangible assets	(35,000)	—
Net cash used in investing activities	(200,428)	(24,960)
Financing activities
Proceeds from issuance of convertible notes, net of issuance costs of $17,954	672,046	—
Exchange and repurchase of 2029 convertible notes	(536,080)	—
Proceeds from issuance of common stock and pre-funded warrants in private placement, net of issuance costs of $8,600	259,948	—
Proceeds from issuance of common stock pursuant to equity plans	31,260	31,143
Net cash provided by financing activities	427,174	31,143
Effect of exchange rate on cash, cash equivalents and restricted cash	(2,662)	3,630
Net (decrease) increase in cash, cash equivalents and restricted cash	(53,242)	59,573
Cash, cash equivalents and restricted cash at beginning of period	298,165	222,928
Cash, cash equivalents and restricted cash at end of period	$244,923	$282,501

Condensed Consolidated Statements of Cash Flows

	Nine Months Ended September 30,
	2026	2025
Supplemental disclosure of cash flow information:
Operating cash flows paid for operating leases	$2,398	$1,904
Cash paid for interest	$7,003	$6,325
Cash paid for income taxes	$3,281	$2,151
Net operating liabilities, excluding cash acquired, assumed in connection with asset acquisition	$9,561	$—
Non-cash operating, investing and financing activities:
Reduction in additional paid-in capital related to the exchange and repurchase of notes maturing in 2029	$600,881	$—
Shares issued in connection with the exchange and repurchase of convertible notes maturing in 2029	$329,089	$—
Accrued milestone payments classified as intangible assets, net	$35,000	$—
Right-of-use assets obtained in exchange for lease liabilities	$4,472	$1,673
Decrease in ROU assets and lease liabilities due to lease modification	$—	$649
Stock option exercise proceeds receivable	$199	$—
Stock-based compensation capitalized to inventory	$571	$543
Conversion of convertible notes, net into shares of common stock	$4	$17

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.